Harvard Bioscience Inc

HBIONASDAQ · USD
8.68USD+3.77 (-3.56%)
615

Harvard Bioscience Inc (HBIO) Covered Calls

Read more

Running HBIO covered calls helps you generate income from Harvard Bioscience Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best HBIO covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If HBIO stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling HBIO covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given HBIO covered call is worth writing.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

No illustrative rows to display.

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryMedical Instruments & Supplies
  • SectorHealthcare
  • IV Rank48.81% Moderate
  • Market cap (M$)22
  • 52 weeks high-39.75%
  • 52 weeks low102.85%
  • Analyst recommendationBuy
    2.00
  • Target price$6.00
    -30.88% below the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-05-11
  • P/E—
  • Future P/E6.14
  • EPS (ttm)-12.85
  • EPS growth next 5 years—

As of Nov 19, 2026